Researchers developed a brain-delivered antibody capable of targeting pathological alpha-synuclein aggregates, which characterize synucleinopathies like Parkinson’s disease. This approach offers a potential therapeutic avenue to mitigate neurodegeneration by directly engaging disease-specific protein aggregates.